Skip to main content
. 2016 May 12;6:25740. doi: 10.1038/srep25740

Figure 6. Gouty patients express higher protein levels of ALPK1, myosin, and plasma TNF-α.

Figure 6

(A) In vitro human assays of freshly isolated monocytes from twenty gout patients and ten healthy controls were analysed for the levels of ALPK1, myosin IIA, and plasma TNF-α. Eight gout patients (no. 3, 5 12, 14, 17, 18, 19, 20; details refer to in Supplementary Table 3) who were medicated with a combined benzbromarone and colchicine showed lower plasma TNF-α than the remaining twelve gout patients who were nonmdicated. (B) Gout patients were pooled to show they expressed more ALPK1, however no difference was observed between medicated and nonmedicated groups (left), gout patients expressed more myosin IIA, which was reduced in the medicated group (central), gout patients have higher levels of plasma TNF-α (right), especially in the nonmedicated (60.5 ± 8.7 pg/mL) than medicated patients (39.2 ± 9.7 pg/mL) or healthy controls (18.8 ± 12.6 pg/mL). (C) In vitro effect of medication (benzbromarone, colchicine, or combined of two medications) showed a high dose colchicine (1 mM) had reduced myosin IIA. There was no effect on ALPK1 expression. The THP-1 cells had been incubated with 100 nM PMA for 3 h and then treated with 100 μg/ml MSU for 16 h.